Literature DB >> 18829761

Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells.

Caroline Goujon1, Vanessa Arfi, Thomas Pertel, Jeremy Luban, Julia Lienard, Dominique Rigal, Jean-Luc Darlix, Andrea Cimarelli.   

Abstract

Human immunodeficiency virus type 2 (HIV-2)/simian immunodeficiency virus SIV(SM) Vpx is incorporated into virion particles and is thus present during the early steps of infection, when it has been reported to influence the nuclear import of viral DNA. We recently reported that Vpx promoted the accumulation of full-length viral DNA following the infection of human monocyte-derived dendritic cells (DCs). This positive effect was exerted following the infection of DCs with cognate viruses and with retroviruses as divergent as HIV-1, feline immunodeficiency virus, and even murine leukemia virus, leading us to suggest that Vpx counteracted an antiviral restriction present in DCs. Here, we show that Vpx is required, albeit to a different extent, for the infection of all myeloid but not of lymphoid cells, including monocytes, macrophages, and monocytoid THP-1 cells that had been induced to differentiate with phorbol esters. The intracellular localization of Vpx was highly heterogeneous and cell type dependent, since Vpx localized differently in HeLa cells and DCs. Despite these differences, no clear correlation between the functionality of Vpx and its intracellular localization could be drawn. As a first insight into its function, we determined that SIV(SM)/HIV-2 and SIV(RCM) Vpx proteins interact with the DCAF1 adaptor of the Cul4-based E3 ubiquitin ligase complex recently described to associate with HIV-1 Vpr and HIV-2 Vpx. However, the functionality of Vpx proteins in the infection of DCs did not strictly correlate with DCAF1 binding, and knockdown experiments failed to reveal a functional role for this association in differentiated THP-1 cells. Lastly, when transferred in the context of a replication-competent viral clone, Vpx was required for replication in DCs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829761      PMCID: PMC2593360          DOI: 10.1128/JVI.01181-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  High levels of transduction of human dendritic cells with optimized SIV vectors.

Authors:  Philippe-Emmanuel Mangeot; Karine Duperrier; Didier Nègre; Bertrand Boson; Dominique Rigal; François-Loïc Cosset; Jean-Luc Darlix
Journal:  Mol Ther       Date:  2002-03       Impact factor: 11.454

2.  A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm).

Authors:  M A Accola; A A Bukovsky; M S Jones; H G Göttlinger
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  Functional analysis of the simian immunodeficiency virus Vpx protein: identification of packaging determinants and a novel nuclear targeting domain.

Authors:  S Mahalingam; B Van Tine; M L Santiago; F Gao; G M Shaw; B H Hahn
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

4.  Cellular distribution and karyophilic properties of matrix, integrase, and Vpr proteins from the human and simian immunodeficiency viruses.

Authors:  C Depienne; P Roques; C Créminon; L Fritsch; R Casseron; D Dormont; C Dargemont; S Benichou
Journal:  Exp Cell Res       Date:  2000-11-01       Impact factor: 3.905

5.  NMR structure of the HIV-1 regulatory protein VPR.

Authors:  N Morellet; S Bouaziz; P Petitjean; B P Roques
Journal:  J Mol Biol       Date:  2003-03-14       Impact factor: 5.469

6.  Identification of the nuclear localization signal of human immunodeficiency virus type 2 Vpx.

Authors:  Michael Belshan; Lee Ratner
Journal:  Virology       Date:  2003-06-20       Impact factor: 3.616

7.  Vpx and Vpr proteins of HIV-2 up-regulate the viral infectivity by a distinct mechanism in lymphocytic cells.

Authors:  Fumiko Ueno; Hiroshi Shiota; Maki Miyaura; Akiko Yoshida; Akiko Sakurai; Junko Tatsuki; A Hajime Koyama; Hirofumi Akari; Akio Adachi; Mikako Fujita
Journal:  Microbes Infect       Date:  2003-04       Impact factor: 2.700

8.  Heterologous human immunodeficiency virus type 1 lentiviral vectors packaging a simian immunodeficiency virus-derived genome display a specific postentry transduction defect in dendritic cells.

Authors:  Caroline Goujon; Loraine Jarrosson-Wuilleme; Jeanine Bernaud; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  Characterization of the early steps of infection of primary blood monocytes by human immunodeficiency virus type 1.

Authors:  Vanessa Arfi; Lise Rivière; Loraine Jarrosson-Wuillème; Caroline Goujon; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

10.  Nuclear pore complexes form immobile networks and have a very low turnover in live mammalian cells.

Authors:  N Daigle; J Beaudouin; L Hartnell; G Imreh; E Hallberg; J Lippincott-Schwartz; J Ellenberg
Journal:  J Cell Biol       Date:  2001-07-09       Impact factor: 10.539

View more
  87 in total

1.  Functional mechanisms of the cellular prion protein (PrP(C)) associated anti-HIV-1 properties.

Authors:  Sandrine Alais; Ricardo Soto-Rifo; Vincent Balter; Henri Gruffat; Evelyne Manet; Laurent Schaeffer; Jean Luc Darlix; Andrea Cimarelli; Graça Raposo; Théophile Ohlmann; Pascal Leblanc
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

2.  Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase.

Authors:  Rebecca D Powell; Paul J Holland; Thomas Hollis; Fred W Perrino
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

3.  Comparative analysis of transduced primary human dendritic cells generated by the use of three different lentiviral vector systems.

Authors:  Elena Grabski; Zoe Waibler; Silke Schüle; Björn-Philipp Kloke; Linda Y Sender; Sylvia Panitz; Klaus Cichutek; Matthias Schweizer; Ulrich Kalinke
Journal:  Mol Biotechnol       Date:  2011-03       Impact factor: 2.695

4.  Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 proviral DNA synthesis kinetics in human primary monocyte-derived macrophages.

Authors:  Baek Kim; Laura A Nguyen; Waaqo Daddacha; Joseph A Hollenbaugh
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

Review 5.  The functions of the HIV1 protein Vpr and its action through the DCAF1.DDB1.Cullin4 ubiquitin ligase.

Authors:  Laurieann Casey; Xiaoyun Wen; Carlos M C de Noronha
Journal:  Cytokine       Date:  2010-03-27       Impact factor: 3.861

6.  Stimulation of HIV-1 replication in immature dendritic cells in contact with primary CD4 T or B lymphocytes.

Authors:  Vincent Holl; Ke Xu; Maryse Peressin; Alexandre Lederle; Marina Elizabeth Biedma; Maryse Delaporte; Thomas Decoville; Sylvie Schmidt; Géraldine Laumond; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

7.  Interaction of Vpx and apolipoprotein B mRNA-editing catalytic polypeptide 3 family member A (APOBEC3A) correlates with efficient lentivirus infection of monocytes.

Authors:  André Berger; Carsten Münk; Matthias Schweizer; Klaus Cichutek; Silke Schüle; Egbert Flory
Journal:  J Biol Chem       Date:  2010-02-23       Impact factor: 5.157

Review 8.  Innate antiviral immune signaling, viral evasion and modulation by HIV-1.

Authors:  Arjun Rustagi; Michael Gale
Journal:  J Mol Biol       Date:  2013-12-08       Impact factor: 5.469

Review 9.  Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr?

Authors:  Diana Ayinde; Claire Maudet; Catherine Transy; Florence Margottin-Goguet
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

10.  Restriction of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj.

Authors:  Silke Schüle; Björn-Philipp Kloke; Julia K Kaiser; Sabine Heidmeier; Sylvia Panitz; Nina Wolfrum; Klaus Cichutek; Matthias Schweizer
Journal:  PLoS One       Date:  2009-09-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.